China In Vitro Diagnostics (IVD) Quality Control Market (2025-2030)
The China In Vitro Diagnostics (IVD) Quality Control Market was valued at $105.2 Million in 2025 and projected to reach to $157.4 Million by 2030, representing a compound annual growth rate of 8.4%. China's In Vitro Diagnostics Quality Control Market is positioned for sustained growth, expanding from USD 105.2 million in 2025 to USD 157.4 million by 2030.
China In Vitro Diagnostics (IVD) Quality Control Market Trends and Insights
- China's market growth significantly outpaces the global average of 5.5% CAGR, driven by the country's rapid healthcare modernization, increased diagnostic testing volumes, and stringent regulatory requirements for laboratory quality assurance.
- China's investment in healthcare infrastructure and rising demand for accurate diagnostic results are accelerating adoption of advanced quality control solutions across clinical laboratories and diagnostic centers. The market in China is characterized by growing awareness of quality standards and compliance mandates that require robust quality control protocols.
- China's expanding middle class and aging population are driving higher diagnostic testing demand, which in turn necessitates sophisticated quality control measures.
- By 2030, China is expected to solidify its position as a critical market for IVD quality control solutions, with the country's 8.4% CAGR reflecting strong institutional and commercial laboratory investments in quality assurance technologies..
Key Market Statistics
- CAGR (2025-2030) 8.4% CAGR
- Market Size, 2025 ~USD 105.2 Million
- Forecast, 2030 ~USD 157.4 Million
- Country China
China In Vitro Diagnostics (IVD) Quality Control Market Overview
Rapid Market Expansion :
China's IVD Quality Control Market is growing at 8.4% CAGR, significantly outpacing the global average of 5.5%, reflecting accelerated healthcare infrastructure development and diagnostic modernization across the nation.
Regulatory Compliance Drivers :
Stringent Chinese regulatory requirements for laboratory diagnostics and quality assurance are compelling healthcare facilities to invest in advanced quality control solutions, creating sustained market demand.
Increased Testing Volumes :
Rising diagnostic testing volumes driven by China's aging population, chronic disease prevalence, and expanded healthcare access are directly fueling demand for robust quality control systems in clinical laboratories.
Healthcare Modernization Investment :
China's substantial government investment in healthcare infrastructure modernization and laboratory automation is accelerating adoption of sophisticated IVD quality control technologies across urban and emerging markets.
China In Vitro Diagnostics (IVD) Quality Control Market Dynamics
- This trajectory reflects China's commitment to healthcare modernization, increased diagnostic testing demands, and evolving regulatory standards that mandate rigorous quality assurance protocols in clinical laboratories nationwide. The market's outperformance relative to global benchmarks underscores China's unique growth catalysts, including rising healthcare expenditure, laboratory automation adoption, and stringent government oversight of diagnostic accuracy.
- Strategic investments by both domestic and international players in quality control technologies will continue driving market expansion through 2030..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- China's IVD Quality Control Market is valued at USD 105.2 million in 2025 and will grow to USD 157.4 million by 2030, representing an 8.4% CAGR.
- China's market growth rate of 8.4% CAGR significantly exceeds the global average of 5.5%, positioning China as a high-growth region for IVD quality control solutions.
- China's healthcare modernization, regulatory compliance requirements, and rising diagnostic testing volumes are primary drivers of quality control market expansion.
- China's aging population and expanding middle class are increasing demand for diagnostic services, creating sustained growth opportunities for quality control providers through 2030.
In Vitro Diagnostics (IVD) Quality Control Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | MOLECULAR DIAGNOSTICS (Technology) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 5.5% from 2025 to 2030 |
| Largest Segment | QUALITY CONTROL PRODUCTS (Product & Service) |
| Market Size Base Year (Billions) | ~USD 1.65 (2025) |
| Revenue Forecast (Billions) | ~USD 2.15 (2030) |
| Segments Covered | Product & Service, Type, Technology, Manufacturer Type, End User |
China In Vitro Diagnostics (IVD) Quality Control Market Report Segmentation
5 segment dimensions are covered across the global market.
By Product & Service
- Data Management Solutions
- Quality Assurance Services
- Quality Control Products
By Type
- Independent Controls
- Instrument-Specific Controls
- Other Controls
- Serum/Plasma-Based Controls
- Urine-Based Controls
- Whole Blood-Based Controls
By Technology
- Clinical Chemistry
- Coagulation & Hemostasis
- Hematology
- Immunoassays
- Microbiology
- Molecular Diagnostics
- Other Technologies
By Manufacturer Type
- Original Equipment Manufacturer Controls
- Third-Party Controls
By End User
- Academic & Research Institutes
- Clinical Laboratories
- Hospitals
- Other End Users
Target Audience
- IVD Manufacturers & Suppliers : Companies developing quality control products and diagnostic solutions need China-specific market data to assess growth potential, competitive positioning, and regulatory requirements for successful market penetration.
- Healthcare Facility Operators : Hospital networks, diagnostic laboratories, and clinical centers require market insights to benchmark quality control investments, understand technology trends, and optimize laboratory operations in China's evolving healthcare landscape.
- Investment & Private Equity Firms : Investors evaluating opportunities in China's healthcare sector need validated market sizing, growth projections, and trend analysis to assess investment returns and identify promising portfolio companies in IVD quality control.
- Healthcare Consultants & Advisors : Management consulting firms and healthcare advisors require detailed China market data to support client strategy development, market entry planning, and competitive analysis in the diagnostics quality control space.
- Government & Regulatory Bodies : Healthcare policymakers and regulatory agencies benefit from comprehensive market intelligence to inform healthcare infrastructure planning, quality standards development, and resource allocation decisions across China's laboratory sector.
Key Companies in the China In Vitro Diagnostics (IVD) Quality Control Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOMERIEUX S.A. | France | Public Company | Clinical microbiology (VITEK, culture media, ID/AST, BACT/ALERT),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS),Immunoassays and biomarkers (VIDAS, Hybiome CLIA, sepsis markers), |
| CEPHEID INC. | United States | Private Company | GeneXpert instruments and Xpert test cartridges,SmartCycler systems and assays,Collaborative and program-based solutions (e.g., TB, Ebola, USPS BDS), |
| IMMUCOR, INC. | United States | Private Company | Transfusion (serology instruments and reagents),Transplant & Molecular (HLA, HEA/HPA typing, Array Imaging System),Platelet-focused and specialty coagulation products, |
| DIASORIN | Italy | Public Company | Immunodiagnostics – Infectious and Gastrointestinal Diseases,Immunodiagnostics – Endocrinology and Metabolic Disorders,Oncology and Tumor Markers, |
| UNILABS | Switzerland | Private Company | Core laboratory testing,Medical imaging services,Pathology and centres of excellence, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research Instruments and Reagents,Other and Services, |
| THERMO FISHER SCIENTIFIC, INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| ABBOTT | United States | Public Company | Diagnostic Products (core lab, rapid, molecular, cardiometabolic, drug testing),Medical Devices (cardiovascular, diabetes care, neuromodulation),Nutritional Products (pediatric, adult, infant formula), |
| LGC LIMITED | South Korea | Public Company | Ethylene-based synthetic resins (EVA, HDPE, LDPE, LLDPE, POE, metallocene PE, UNIQABLE),Styrene-based resins (ABS, ASA, EPS, PS, SAN),Polycarbonate and polypropylene, |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| QUIDELORTHO CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care (professional and OTC), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and related solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables), |
| SYSMEX CORPORATION | Japan | Public Company | Hematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems and reagents,Blood gas, electrolyte, and urinalysis analyzers, |
| BIO-TECHNE CORPORATION | United States | Public Company | Protein Sciences reagents (cytokines, growth factors, antibodies, small molecules, sera, cell selection),Proteomic and protein analysis instruments and immunoassays,Diagnostics products, controls, calibrators, and assays, |
| MICROBIX BIOSYSTEMS INC. | Canada | Public Company | Antigen and test ingredient business,QAPs branded test controls and quality assessment products,DxTM viral transport medium, |
| GRIFOLS, S.A. | Spain | Public Company | Biopharma (plasma-derived medicines),Diagnostic,Bio Supplies, |
BIOMERIEUX S.A.
bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.
CEPHEID INC.
Cepheid Inc. is a private company founded in 1996 in the United States with 1,700 employees. The company specializes in molecular diagnostics and infectious disease testing.
IMMUCOR, INC.
Immucor, Inc. is a private company founded in 1982 in the United States with 1,125 employees. The company focuses on blood bank and transfusion diagnostics.
DIASORIN
DiaSorin is an Italian public company founded in 1968 with 3,242 employees. The company operates in the in vitro diagnostics sector.
UNILABS
Unilabs is a private company founded in 1987 in Switzerland with 1,897 employees. The company provides laboratory and diagnostic services.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States with 7,450 employees. The company develops and manufactures life science research and clinical diagnostics products.
THERMO FISHER SCIENTIFIC, INC.
Thermo Fisher Scientific, Inc. is a public company founded in 1956 in the United States with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.
ABBOTT
Abbott is a public company founded in 1888 in the United States with 115,000 employees. The company operates in diagnostics, medical devices, pharmaceuticals, and nutritional products.
LGC LIMITED
LGC Limited is a public company founded in 1947 in South Korea with 14,019 employees. The company provides testing, proficiency testing, and reference materials services.
SIEMENS HEALTHINEERS AG
Siemens Healthineers AG is a public company founded in 1896 in Germany with 72,369 employees. The company provides medical imaging, laboratory diagnostics, and point-of-care testing solutions.
QUIDELORTHO CORPORATION
QuidelOrtho Corporation is a public company founded in 1979 in the United States with 6,500 employees. The company develops and manufactures rapid diagnostic tests and molecular testing solutions.
DANAHER CORPORATION
Danaher Corporation is a public company founded in 1969 in the United States with 59,000 employees. The company operates across diagnostics, life sciences, and environmental and applied solutions segments.
SYSMEX CORPORATION
Sysmex Corporation is a public company founded in 1968 in Japan with 10,861 employees. The company manufactures hematology analyzers and other in vitro diagnostic systems.
BIO-TECHNE CORPORATION
Bio-Techne Corporation is a public company founded in 1976 in the United States with 3,100 employees. The company develops and manufactures life science tools and bioanalytical instruments.
MICROBIX BIOSYSTEMS INC.
Microbix Biosystems Inc. is a public company founded in 1988 in Canada with 100 employees. The company produces quality control materials and reference standards for diagnostics.
GRIFOLS, S.A.
Grifols, S.A. is a public company founded in 1909 in Spain with 25,000 employees. The company specializes in blood plasma derivatives and diagnostic products.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation data for China's IVD Quality Control sector with verified 8.4% CAGR projections through 2030, enabling accurate financial forecasting and investment decision-making.
- Competitive Landscape Intelligence : Understand China-specific market dynamics, regulatory drivers, and competitive positioning to identify opportunities for market entry, expansion, or strategic partnerships in this high-growth healthcare segment.
- Regulatory & Compliance Insights : Access detailed analysis of China's stringent laboratory diagnostic regulations and quality control requirements, essential for developing compliant products and services tailored to local market standards.
- Growth Driver Analysis : Leverage comprehensive insights into China's healthcare modernization initiatives, aging population trends, and diagnostic testing volume increases to identify emerging market opportunities and demand catalysts.
- Strategic Planning & Forecasting : Utilize 2025-2030 market projections and trend analysis specific to China to develop informed business strategies, resource allocation plans, and long-term growth initiatives in the IVD quality control sector.
Frequently asked questions
What is the current size of China's IVD Quality Control Market in 2025?
China's In Vitro Diagnostics Quality Control Market is valued at USD 105.2 million in 2025.
What is the projected market size for China's IVD Quality Control Market by 2030?
China's IVD Quality Control Market is projected to reach USD 157.4 million by 2030.
What is the CAGR for China's IVD Quality Control Market from 2025 to 2030?
China's IVD Quality Control Market is expected to grow at a compound annual growth rate (CAGR) of 8.4% from 2025 to 2030.
How does China's IVD Quality Control Market growth compare to global growth?
China's market CAGR of 8.4% significantly outpaces the global CAGR of 5.5%, indicating China is a faster-growing market for IVD quality control solutions.
What factors are driving growth in China's IVD Quality Control Market?
Key drivers include China's healthcare modernization, stringent regulatory compliance requirements, increased diagnostic testing volumes, an aging population, and rising middle-class demand for diagnostic services.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the global IVD quality controls market.
Exhaustive secondary research was done to collect information on the IVD quality controls market. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the IVD quality controls market.
The four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenue. Here’s the breakdown of tiers: Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both the top-down and bottom-up approaches were used to estimate and validate the IVD quality controls market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
IVD quality controls are standardized materials used to monitor, evaluate, and ensure the accuracy, reliability, and precision of diagnostic testing processes in clinical laboratories. These controls are designed to mimic patient samples and are produced from human-derived matrices such as serum, plasma, urine, or whole blood. IVD quality controls provide a benchmark for validating test system performance, detecting errors, and ensuring regulatory compliance across diverse diagnostic platforms.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global IVD quality controls market by product & service, technology, manufacturer type, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall IVD quality controls market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the IVD quality controls market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region
Get the Full In Vitro Diagnostics (IVD) Quality Control Market Report
Full forecast, segment splits, and company analysis for all In Vitro Diagnostics (IVD) Quality Control Market.
- Canada In Vitro Diagnostics (IVD) Quality Control Market
- US In Vitro Diagnostics (IVD) Quality Control Market
- Germany In Vitro Diagnostics (IVD) Quality Control Market
- UK In Vitro Diagnostics (IVD) Quality Control Market
- France In Vitro Diagnostics (IVD) Quality Control Market
- Italy In Vitro Diagnostics (IVD) Quality Control Market
- Spain In Vitro Diagnostics (IVD) Quality Control Market
- Russia In Vitro Diagnostics (IVD) Quality Control Market
- Japan In Vitro Diagnostics (IVD) Quality Control Market
- India In Vitro Diagnostics (IVD) Quality Control Market
- Australia In Vitro Diagnostics (IVD) Quality Control Market
- South Korea In Vitro Diagnostics (IVD) Quality Control Market
- Brazil In Vitro Diagnostics (IVD) Quality Control Market
- Mexico In Vitro Diagnostics (IVD) Quality Control Market
- Saudi Arabia In Vitro Diagnostics (IVD) Quality Control Market
- UAE In Vitro Diagnostics (IVD) Quality Control Market
- Rest Of Europe In Vitro Diagnostics (IVD) Quality Control Market
- Rest Of Asia Pacific In Vitro Diagnostics (IVD) Quality Control Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report